-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

652.O5.6 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Challenges in Multiple Myeloma Therapy: Adopting New Approaches for Relapse and Monitor

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Biological, Genomics, Bispecific Antibody Therapy, Clinical Research, Plasma Cell Disorders, Diseases, Therapies, Immunotherapy, Lymphoid Malignancies, Monoclonal Antibody Therapy
Monday, December 13, 2021: 4:30 PM-6:00 PM
Hall A1 (Georgia World Congress Center)
Moderators:
Wendy Cozen, DO, MPH, Susan and Henry Samueli College of Health Sciences, University of California at Irvine, University of California at Irvine and Shaji K Kumar, MD, Mayo Clinic
Disclosures:
Kumar: Astra-Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Consultancy, Research Funding; Novartis: Research Funding; Tenebio: Research Funding; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Beigene: Consultancy; Oncopeptides: Consultancy; Antengene: Consultancy, Honoraria; Carsgen: Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Research Funding; Roche-Genentech: Consultancy, Research Funding; Bluebird Bio: Consultancy; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Research Funding.
4:30 PM

Jonathan L. Kaufman, MD1, Hang Quach, FRACP, FRCPA2, Rachid Baz, MD3*, Annette J. Vangsted, MD4*, Shir-Jing Ho, FRACP, FRCPA, MBBS5*, Simon J Harrison, MD6, Torben Plesner, MD7, Philippe Moreau, MD, PhD8*, Simon D. Gibbs9*, Eva Medvedova, MD10*, Vasudha Sehgal, PhD11*, Kingston Kang, PhD12*, Jeremy A. Ross, PhD11*, L. Leanne Lash-Fleming, PhD12*, Yan Luo, MD PhD12* and Nizar J. Bahlis, MD13

1Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
2St. Vincent’s Hospital, Melbourne, VIC, Australia
3Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
4Department of Hematology, Rigshospitalet, Copenhagen, Denmark
5St George Hospital, Kogarah, AUS
6Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
7Department of Hematology, Vejle Hospital, Vejle, Denmark
8University Hospital Hôtel-Dieu, Nantes, Nantes, France
9The Victorian and Tasmanian Amyloidosis Service, Department of Haematology, Monash University Easter Health Clinical School, Melbourne, VIC, Australia
10Oregon Health & Science University, Portland, OR
11AbbVie Inc., North Chicago, IL
12AbbVie, Inc., North Chicago, IL
13Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada

4:45 PM

Xiang Zhou1*, Andrej Besse2*, Jessica Peter, MD3*, Max Mendez Lopez, MD4*, Larissa Haertle5*, Umair Munawar, PhD6*, Seungbin Han3*, Elmer Maurits7*, Herman S. Overkleeft8*, Hermann Einsele9, Christoph Driessen, MD10, Martin Kortuem11*, Lenka Besse12* and Leo Rasche, MD13*

1Department of Internal Medicine II, Division of Oncology and Hematology, University Hospital Wuerzburg, WüRzburg, Germany
2Kantonsspital St. Gallen, St.Gallen, CHE
3University Hospital Würzburg, Würzburg, Germany
4Cantonal Hoapital St Gallen, St Gallen, Switzerland
5Department of Internal Medicine II, University Hospital WüRzburg, W, WüRzburg, DEU
6Department of Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany
7Leiden Institute of Chemistry and Netherlands Proteomics Centre, Leiden, Netherlands
8Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands
9Department of Internal Medicine II, Division of Oncology and Hematology, Würzburg University Hospital, Würzburg, Germany
10Department of Oncology and Hematology, Laboratory of Experimental Oncology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland
11Department of Internal Medicine II, University Hospital Wuerzburg, Wuerzburg, Germany
12Department of Oncology and Hematology, Laboratory of Experimental Oncology, Kantonal Hospital St Gallen, St Gallen, Switzerland
13University Hospital Würzburg, Würzburg, Bayern, Germany

5:00 PM

Sarah Goldman-Mazur, MD1*, Alissa Visram, MD2,3*, S Vincent Rajkumar, MD4*, Prashant Kapoor, MD3, Angela Dispenzieri, MD3, Martha Q. Lacy, MD1, Morie A. Gertz, M.D.3, Francis K. Buadi, MB, CHB5*, Suzanne R. Hayman, M.D.3, David Dingli, M.D., Ph.D.3, Taxiarchis Kourelis, M.D.3, Wilson I Gonsalves, MD3, Rahma M Warsame, MD3, Eli Muchtar, MD3*, Nelson Leung, MD1, Robert A. Kyle, MD3 and Shaji K Kumar, MD6

1Division of Hematology, Mayo Clinic Rochester, Rochester, MN
2Division of Hematology, Ottawa Hospital Research Institute, Ottawa, ON, Canada
3Division of Hematology, Mayo Clinic, Rochester, MN
4Division of Hematology, Mayo Clinic, Rochester
5Mayo Clinic Rochester, Division of Hematology, Rochester, MN
6Mayo Clinic, Rochester, MN

5:15 PM

Hannah Victoria Giles, FRCPath, MRCP1*, Mark T Drayson, MD2*, Nicola Wright, MChem3*, Gordon Cook, MD4,5*, Faith E. Davies6*, Gareth J Morgan, MD, PhD6*, Ruth M. de Tute, PhD, FRCPath7*, Roger G Owen, MD8*, David Cairns, PhD5*, Anna Hockaday9*, Tom Menzies5*, Martin F. Kaiser, MD, FRCP, FRCPath10, Charlotte Pawlyn, BA, MB BChir, PhD, MRCP, FRCPath11, Graham Jackson, MBBS, FRCP, FRCPath, MA, DM12 and Guy Pratt, MD FRCP FRCPath13,14

1University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, United Kingdom
2Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
3The Binding Site Ltd, Birmingham, United Kingdom
4Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
5Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
6NYU Langone Health, Myeloma Research Program, Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY
7Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, United Kingdom
8St. James's University Hospital, Leeds, United Kingdom
9Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, Leeds, United Kingdom
10The Institute of Cancer Research, London, United Kingdom
11Institute of Cancer Research, Sutton, United Kingdom
12Department of Haematology, NCCC Freeman Road Hospital, Newcastle Upon Tyne, United Kingdom
13Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom
14University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

5:30 PM

Tarek H. Mouhieddine, MD1, Oliver Van Oekelen, MD, MSc2, Darren Pan, MD, BS3*, Sarita Agte, MD4*, Adolfo Aleman, MPA2*, David T. Melnekoff, MS5*, Guido Lancman, MD3, Santiago Thibaud, MD6, Larysa Sanchez, MD4*, Shambavi Richard3*, Joshua Richter, MD3, Hearn Jay Cho, MD, PhD3, Ajai Chari, MD7, Sundar Jagannath8 and Samir Parekh, MD3

1Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
2Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
3Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
4Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
5Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, Brooklyn, NY
6Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
7Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
8Department of Medicine, Hematology and Medical Oncology, Mount Sinai Medical Center, New York, NY

5:45 PM

Oliver Van Oekelen, MD, MSc1,2,3, Sarita Agte, MD2,4*, Adolfo Aleman, MPA2,3*, Bhaskar Upadhyaya, PhD2,4*, Charles R. Gleason, BS5*, Komal Srivastava, MS5*, Katherine F. Beach, BA5*, Kevin Tuballes, MD6,7*, Katerina Kappes, BSc2,4*, Tarek H. Mouhieddine, MD8, Bo Wang, MD4*, Seunghee Kim-Schulze, PhD2,6*, Ajai Chari, MD4,9*, Sacha Gnjatic, PhD2,6,7,10*, Nina Bhardwaj, MD, PhD2,4,7,11*, Brian D. Brown, PhD1,2,7*, Miriam Merad, MD2,4,6,7,10*, Carlos Cordon-Cardo, MD, PhD1,10,12*, Florian Krammer, PhD5,13*, Sundar Jagannath, MD2,4*, Viviana Simon, MD, PhD5,14,15*, Ania Wajnberg, MD16,17* and Samir Parekh, MD2,4,7,10

1Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
3Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
4Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
5Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY
6Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY
7Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY
8Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
9Mount Sinai, New York, NY
10Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
11Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY
12Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
13Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY
14Department of Medicine, Division of Infectious Disease, Icahn School of Medicine at Mount Sinai, New York, NY
15Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, New York, NY
16Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
17Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

*signifies non-member of ASH